Victory Capital Management Inc. trimmed its position in Bruker Co. (NASDAQ:BRKR - Free Report) by 34.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 19,647 shares of the medical research company's stock after selling 10,133 shares during the period. Victory Capital Management Inc.'s holdings in Bruker were worth $1,152,000 as of its most recent filing with the SEC.
A number of other large investors also recently modified their holdings of BRKR. VELA Investment Management LLC bought a new position in Bruker during the 4th quarter worth $1,187,000. Proficio Capital Partners LLC bought a new position in Bruker during the 4th quarter worth $608,000. Bank of New York Mellon Corp raised its position in Bruker by 7.6% during the 4th quarter. Bank of New York Mellon Corp now owns 988,863 shares of the medical research company's stock worth $57,967,000 after purchasing an additional 69,806 shares during the last quarter. South Dakota Investment Council bought a new position in Bruker during the 4th quarter worth $703,000. Finally, Ieq Capital LLC raised its position in Bruker by 961.0% during the 4th quarter. Ieq Capital LLC now owns 58,950 shares of the medical research company's stock worth $3,456,000 after purchasing an additional 53,394 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.
Bruker Stock Down 0.0 %
Shares of BRKR traded down $0.02 during trading hours on Friday, hitting $44.45. The stock had a trading volume of 2,205,246 shares, compared to its average volume of 1,308,664. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The firm has a 50 day simple moving average of $52.16 and a 200-day simple moving average of $57.69. The firm has a market capitalization of $6.74 billion, a P/E ratio of 58.49, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a 1-year low of $43.51 and a 1-year high of $94.64.
Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Sell-side analysts predict that Bruker Co. will post 2.69 EPS for the current fiscal year.
Bruker Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Monday, March 17th. Bruker's dividend payout ratio is currently 26.32%.
Analyst Ratings Changes
Several brokerages recently issued reports on BRKR. The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price for the company in a research report on Thursday, December 5th. Barclays decreased their price target on Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Stifel Nicolaus decreased their price target on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, Bank of America increased their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Bruker presently has an average rating of "Moderate Buy" and an average price target of $70.50.
Read Our Latest Analysis on BRKR
Bruker Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
